Roche Secures Dicerna RNAi Deal For Hepatitis B
Roche Pays $200m Up Front For DCR-HBVS Candidate
Roche has paid $200m up front to get its hands on Dicerna’s RNAi-based drug for chronic hepatitis B in a deal that could be worth around $1.5bn.
Roche has paid $200m up front to get its hands on Dicerna’s RNAi-based drug for chronic hepatitis B in a deal that could be worth around $1.5bn.